122 related articles for article (PubMed ID: 12094702)
1. [Thyroid carcinoma: genetics, diagnosis, clinical features, and surgical treatment].
Takami H; Ikeda Y; Tajima G; Kan S; Kameyama K
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):492-4. PubMed ID: 12094702
[TBL] [Abstract][Full Text] [Related]
2. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
Komminoth P
Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
[TBL] [Abstract][Full Text] [Related]
3. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
4. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
6. Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation.
Brauckhoff M; Gimm O; Hinze R; Ukkat J; Brauckhoff K; Dralle H
Thyroid; 2002 Jul; 12(7):557-61. PubMed ID: 12193298
[TBL] [Abstract][Full Text] [Related]
7. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.
Niccoli-Sire P; Murat A; Rohmer V; Franc S; Chabrier G; Baldet L; Maes B; Savagner F; Giraud S; Bezieau S; Kottler ML; Morange S; Conte-Devolx B;
J Clin Endocrinol Metab; 2001 Aug; 86(8):3746-53. PubMed ID: 11502806
[TBL] [Abstract][Full Text] [Related]
8. Papillary thyroid carcinoma, parathyroid adenoma, and unexplained hypercalcitoninemia: an unusual presentation of multiple endocrine neoplasia type 2A?
Rone JK; Lane AG; Grinkemeyer MD
Thyroid; 1998 Sep; 8(9):781-5. PubMed ID: 9777749
[TBL] [Abstract][Full Text] [Related]
9. RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.
Pacini F; Elisei R; Romei C; Pinchera A
J Endocrinol Invest; 2000 May; 23(5):328-38. PubMed ID: 10882153
[TBL] [Abstract][Full Text] [Related]
10. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice.
Acton DS; Velthuyzen D; Lips CJ; Höppener JW
Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866
[TBL] [Abstract][Full Text] [Related]
11. [The RET gene in thyroid pathology].
Michiels FM; Billaud M
Arch Anat Cytol Pathol; 1998; 46(1-2):19-30. PubMed ID: 9754357
[TBL] [Abstract][Full Text] [Related]
12. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas.
Jhiang SM; Sagartz JE; Tong Q; Parker-Thornburg J; Capen CC; Cho JY; Xing S; Ledent C
Endocrinology; 1996 Jan; 137(1):375-8. PubMed ID: 8536638
[TBL] [Abstract][Full Text] [Related]
13. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
[TBL] [Abstract][Full Text] [Related]
14. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.
Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP
Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127
[TBL] [Abstract][Full Text] [Related]
15. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
16. Perspective on RET proto-oncogene and thyroid cancer.
Le HN; Norton JA
Cancer J; 2000; 6(2):50-7. PubMed ID: 11069217
[TBL] [Abstract][Full Text] [Related]
17. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
[TBL] [Abstract][Full Text] [Related]
18. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.
Elisei R; Romei C; Vorontsova T; Cosci B; Veremeychik V; Kuchinskaya E; Basolo F; Demidchik EP; Miccoli P; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3211-6. PubMed ID: 11443191
[TBL] [Abstract][Full Text] [Related]
19. Oncogenes and thyroid cancer.
Vecchio G; Santoro M
Clin Chem Lab Med; 2000 Feb; 38(2):113-6. PubMed ID: 10834397
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of thyroid tumors and surgical decision-making.
Learoyd DL; Messina M; Zedenius J; Robinson BG
World J Surg; 2000 Aug; 24(8):923-33. PubMed ID: 10865036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
